Loading
CD70 is a protein normally only on activated immune cells, but permanently switched on in kidney cancer and some leukaemias.
CD70 is the TNF-family ligand for CD27, normally expressed only transiently on activated immune cells, but permanently switched on in clear-cell RCC and a range of haematologic malignancies with minimal normal expression. It is found in 80-90% of clear-cell RCC by IHC and on blasts and leukaemic stem cells in 30-50% of AML, as well as in lymphomas. Allogeneic CD70 CAR-T (ALLO-316) has shown responses in RCC, a notable result because solid tumours have resisted CAR-T. An advantage of the target is that CD70-directed cells may also deplete alloreactive host T cells, which helps off-the-shelf products persist. Durability of response and safety in AML are open. The simple version is an immune-cell protein that kidney cancer keeps switched on, offering a target for donor-derived CAR-T.
In plain words · CD70 is a protein normally only on activated immune cells, but permanently switched on in kidney cancer and some leukaemias.
CD70 is a protein normally only on activated immune cells, but permanently switched on in kidney cancer and some leukaemias.
CD70 is the TNF-family ligand for CD27.
2 products aim at CD70: antibodies and cell therapies. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Lineage antigen shared with normal T-cells and lymphoid tissue cells: HPA blood lineage group enriched at or above 25 nTPM, and 1 cell-killing or cell-finding medicine (ADI-270) aim at it, so normal cells of the lineage are hit too. HPA CD70: RNA tissue enhanced (lymphoid tissue 3 nTPM); blood lineage group enriched (B-cells 24 nTPM, T-cells 44 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Renal cell carcinoma, Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas CD70 tissue; Human Protein Atlas CD70 pathology; Open Targets ENSG00000125726 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Goodwin R.G. et al, Cell, 1993, "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor". Source.
CD70 is the TNF-family ligand for CD27.
RNA: tissue enhanced (lymphoid tissue 3 nTPM), detected in some normal tissues. Blood: group enriched (B-cells 24 nTPM, T-cells 44 nTPM).
No normal tissue stained high.
RNA cancer enhanced: Kidney Renal Clear Cell Carcinoma 97 pTPM.
No cancer sample stained medium or high.
HPA CD70 tissue · HPA CD70 pathology · HPA protein class: CD markers
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Renal cell carcinoma | 80-90% | Clear-cell, IHC | Wikipedia | |
| Acute myeloid leukaemia | 30-50% | Blasts and leukaemic stem cells | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
ADI-270 is an experimental CAR-T cell therapy from Adicet Therapeutics in phase 2 trials for renal cell carcinoma, aimed at CD70.
Cusatuzumab is an experimental monoclonal antibody from OncoVerity in phase 2 trials for acute myeloid leukaemia, aimed at CD70.
Query for this target: (TITLE:"CD70" OR ABSTRACT:"CD70") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD70, not a curated reading list.
Shares CAR-T cell therapy and the tag car-t-target.
Shares Allogene Therapeutics, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy and the tag car-t-target.
Shares ADI-270, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
Shares CAR-T cell therapy and the tag car-t-target.
Shares CAR-T cell therapy and the tag car-t-target.
Shares CAR-T cell therapy and the tag car-t-target.
Shares ADI-270, Renal cell carcinoma.
Shares Cusatuzumab, Acute myeloid leukaemia.